68Ga-NOTA-RM26 PET/CT in the evaluation of glioma: a pilot prospective study

Yilin Li; Rongxi Wang; Jingci Chen; Zhaohui Zhu; Yu Wang; Wenbin Ma

doi:10.1186/s13550-025-01198-7

⁶⁸Ga-NOTA-RM26 PET/CT in the evaluation of glioma: a pilot prospective study

EJNMMI Res. 2025 Jan 17;15(1):6. doi: 10.1186/s13550-025-01198-7.

Authors

Yilin Li^#^{1

2}, Rongxi Wang^#³, Jingci Chen⁴, Zhaohui Zhu^{5

6}, Yu Wang^{7

8}, Wenbin Ma^{9

10}

Affiliations

¹ Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
² Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
³ Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
⁴ Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
⁵ Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. [email protected].
⁶ Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. [email protected].
⁷ Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. [email protected].
⁸ Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. [email protected].
⁹ Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. [email protected].
¹⁰ Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. [email protected].

^# Contributed equally.

PMID: 39821814
DOI: 10.1186/s13550-025-01198-7

Abstract

Background: Gliomas are the most common malignant primary tumors of the central nervous system. There is an urgent need for new convenient, targeted and specific imaging agents for gliomas. This study aimed to firstly evaluate the feasibility of ⁶⁸Ga-NOTA-RM26 PET/CT imaging in glioma and analyze the relationship between the imaging characteristics and glioma grade, classification and molecular alterations.

Results: Twenty-two patients were confirmed as glioma by surgery or biopsy. All patients exhibited ⁶⁸Ga-NOTA-RM26 uptake. SUV_max was chosen as the imaging marker for analysis. For all glioma patients, there were significant differences between grades (P = 0.047). For primary gliomas, SUV_max had good discrimination for both tumor classifications (P = 0.045) and grades (P = 0.03). There was a positive correlation (P < 0.01) between GRPR expression level and SUV_max. P53 mutations caused significant differences in SUV_max (P = 0.03).

Conclusions: This study is the first application of ⁶⁸Ga-NOTA-RM26 in glioma patients and confirmed the safety and efficacy in glioma patients. ⁶⁸Ga-NOTA-RM26 PET/CT has potential value in tumor grade, classification, and molecular alterations.

Trial registration: ClinicalTrials.gov: NCT06412952. Registered 26 April 2024, https://clinicaltrials.gov/study/NCT06412952.

Keywords: 68Ga-NOTA-RM26; Gastrin-releasing peptide receptor (GRPR); Glioma; PET/CT.

Associated data

ClinicalTrials.gov/NCT06412952

Abstract

Associated data

Grants and funding